Drug Information

Drug General Information
Drug ID
D0D7DU
Former ID
DIB007160
Drug Name
VLTS-589
Synonyms
Deltavasc; Del-1 gene therapy, Valentis; Gene therapy (Del-1, PINC), Valentis
Indication Peripheral vascular disease [ICD9: 443.9; ICD10:I73.9] Phase 2 [521572]
Company
Valentis
Target and Pathway
Target(s) Alpha v beta 3 integrin receptor Target Info Modulator [550017]
Reactome Platelet degranulation
Cross-presentation of particulate exogenous antigens (phagosomes)
Elastic fibre formation
PECAM1 interactions
Molecules associated with elastic fibres
Integrin cell surface interactions
Laminin interactions
Syndecan interactions
ECM proteoglycans
Integrin alphaIIb beta3 signaling
GRB2:SOS provides linkage to MAPK signaling for Integrins
p130Cas linkage to MAPK signaling for integrins
VEGFA-VEGFR2 Pathway
MAP2K and MAPK activation
WikiPathways Osteoblast Signaling
Focal Adhesion
Class I MHC mediated antigen processing & presentation
Syndecan interactions
Extracellular matrix organization
Elastic fibre formation
Primary Focal Segmental Glomerulosclerosis FSGS
Arrhythmogenic Right Ventricular Cardiomyopathy
Integrin-mediated Cell Adhesion
L1CAM interactions
Integrin cell surface interactions
Cell surface interactions at the vascular wall
Osteopontin Signaling
References
Ref 521572ClinicalTrials.gov (NCT00068133) Trial of VLTS-589 in Subjects With Intermittent Claudication. U.S. National Institutes of Health.
Ref 550017AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis. 2013(4), Page 35.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.